Prospective randomized trial of prophylaxis of postoperative peritoneal carcinomatosis of advanced gastric cancer: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles.

Han Liang; Pu Wang; Xiao-na Wang; Ning Liu; Xin Yue; Dian-chang Wang; Jia-cang Wang; Xi-shan Hao

Return

Prospective randomized trial of prophylaxis of postoperative peritoneal carcinomatosis of advanced gastric cancer: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles.

Author: Han LIANG ¹ ; Pu WANG ; Xiao-na WANG ; Ning LIU ; Xin YUE ; Dian-chang WANG ; Jia-cang WANG ; Xi-shan HAO
Author Information

1. Department of Gastrointestinal Oncological Surgery, Tianjin Cancer Hospital, Tianjin Medical University, Tianjin 300060, China.
Publication Type:Journal Article
MeSH: Antibiotics, Antineoplastic; administration & dosage; Antineoplastic Agents; administration & dosage; therapeutic use; Charcoal; administration & dosage; Chemotherapy, Cancer, Regional Perfusion; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitomycin; administration & dosage; Neoplasm Recurrence, Local; prevention & control; Peritoneal Cavity; Prognosis; Prospective Studies; Stomach Neoplasms; drug therapy; pathology; Survival Analysis; Treatment Outcome
From: Chinese Journal of Surgery 2003;41(4):274-277
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo evaluate the beneficial effect of intraperitoneally applied mitomycin bound to activated carbon particles (MMC-CH) in the prevention and treatment of intraabdominal recurrence after curative surgery for gastric cancer.
METHODSOne hundred and twenty-four patients with radically resected gastric cancer infiltrating the serosal surface were randomly divided into group receiving 50 mg mitomycin bound to a solution of 375 mg carbon adsorbent intraperitoneally before closure of the abdominal wound (n = 62) and a control group (n = 62). The patients with MMC-CH and the control group were received systemic chemotherapy 3 months or 3 weeks after operation respectively. The postoperative recurrence-free survival was evaluated to analyze the benefits of this treatment.
RESULTSAfter observation for 8 months (range, 2 - 65). The 3-, 5-year postoperative recurrence-free survival rates were significantly higher in the MMC-CH group (70.16%, 44.51%) than in the control group (27.09%, 14.45%), P < 0.01.
CONCLUSIONAdjuvant intraperitoneal chemotherapy of gastric cancer by mitomycin bound to activated carbon particles is effected by an increased postoperative recurrence-free survival rate.